Evidence Hub

Glycyrrhizic Acid Monoammonium Complex (XF-2): Chemical Profile and Immunomodulatory Evaluation

Fayуoza Khurramova, Rakhmat Sulton ugli Esanov, Izzatullo Abdullaev, Ulugbek Gayibov, Kuralbay Zhadigerovich Rezhepov, Alimjan Matchanov

Trends in Sciences, 2026

Abstract

This study explores the physicochemical and biological properties of the supramolecular complex XF-2, composed of glycyrrhizic acid monoammonium salt and anti-tuberculosis drugs pyrazinamide, isoniazid, rifampicin, and levofloxacin. UV-Vis spectroscopy revealed a bathochromic shift from 254 to 264 nm, confirming electronic interactions between glycyrrhizic acid and the guest molecules. FTIR spectra showed characteristic bands at 1,658 cm⁻¹ (C=O) and 1,593 cm⁻¹ (–COO⁻), indicating ionic and hydrogen-bonded interactions responsible for supramolecular assembly formation. Molecular docking analysis demonstrated stable binding of XF-2 components with NF-κB p52 (2AZ5), IL-10 (1VLK), and IL-6 receptor (1A3Q), with binding energies ranging from –4.6 to –9.2 kcal/mol. Rifampicin and levofloxacin exhibited the strongest affinities, forming multiple hydrogen bonds, π-π stacking, and electrostatic interactions with key amino acid residues. In vivo studies showed that XF-2 is low-toxic (LD₅₀ = 4,050 mg/kg) and exerts marked immunomodulatory activity in prednisolone-induced immunosuppressed mice. At 1,000 mg/kg, the complex significantly increased thymus and spleen indices, restoring immune organ weights close to normal values. Together, spectroscopic, computational, and pharmacological data confirm that XF-2 is a stable, safe, and biologically active supramolecular formulation with strong immunorestorative potential, making it a promising candidate for further development as an…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free